FDA Grants Approval for Nitrogycerin ANDA214565 by Padagis Israel
The FDA has granted approval for the ANDA214565 application for Nitrogycerin submitted by Padagis Israel.
Published: July 12, 2026
Updated: July 12, 2026
Author: Humanexa Intelligence
Therapeutic area: Cardiovascular / Angina
Asset: Nitroglycerin
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Nitroglycerin
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Nitrogycerin ANDA214565 by Padagis Israel signifies a new entrant in the cardiovascular market, potentially intensifying competition. Pharma strategy teams must evaluate the implications for their existing products and market positioning.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and any subsequent pricing strategies from Padagis Israel.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.